Compare · INCY vs MEDP
INCY vs MEDP
Side-by-side comparison of Incyte Corp. (INCY) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $25.34B, about 1.6x MEDP ($16.28B).
- Over the past year, INCY is up 45.4% and MEDP is up 23.1% - INCY leads by 22.3 points.
- MEDP has been more active in the news (15 items in the past 4 weeks vs 6 for INCY).
- Both have 25 recent analyst ratings on file.
- Company
- Incyte Corp.
- Medpace Holdings Inc.
- Price
- $124.98+1.45%
- $582.62-1.92%
- Market cap
- $25.34B
- $16.28B
- 1M return
- +5.53%
- +1.58%
- 1Y return
- +45.41%
- +23.10%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 6
- 15
- Recent ratings
- 25
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest INCY
- Incyte to Present at Upcoming Investor Conferences
- Incyte Corp. filed SEC Form 8-K: Other Events
- Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
- EVP, Human Resources Basi Ramitpal K covered exercise/tax liability with 504 shares, decreasing direct ownership by 4% to 10,993 units (SEC Form 4) (withholding obligation)
- President, Global Head of R&D Cagnoni Pablo J sold $1,356,174 worth of shares (10,801 units at $125.56), decreasing direct ownership by 6% to 183,200 units (SEC Form 4)
- Canaccord Genuity initiated coverage on Incyte with a new price target
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,305,422 worth of shares (10,640 units at $122.69), decreasing direct ownership by 5% to 204,804 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 2,207 shares at a strike of $106.47 and sold $273,646 worth of shares (2,207 units at $123.99) (SEC Form 4)
- President, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)
Latest MEDP
- President & CEO Troendle August J. sold $403,176 worth of shares (650 units at $620.27), decreasing direct ownership by 0.12% to 539,894 units (SEC Form 4)
- Innventure Announces Board Leadership Changes to Further Enhance Board Independence and Acceleration of CEO Transition
- Director Kraft Robert O. exercised 3,858 shares at a strike of $84.36 and sold $2,383,511 worth of shares (3,858 units at $617.81) (SEC Form 4)
- President & CEO Troendle August J. sold $2,897,636 worth of shares (4,673 units at $620.08), decreasing direct ownership by 0.86% to 540,544 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)